Identification and assessment of new vaccine candidates for group A streptococcal infections
- PMID: 15246612
- DOI: 10.1016/j.vaccine.2004.01.043
Identification and assessment of new vaccine candidates for group A streptococcal infections
Abstract
Group A Streptococcus (GAS) is a human-specific pathogen responsible for a wide variety of human diseases. Numerous GAS surface antigens interact with the human immune system and only some of these proteins have been studied in depth. A few of these may elicit protective response against GAS infection. In this study, we have used an in silico approach to identify antigenic peptides from GAS surface proteins. Putative GAS surface proteins from the M1 GAS genome were identified by the presence on LPxTG cell-wall anchoring motif and an export signal sequence. This technique identified 17 proteins of known or putative function, and another 11 which do not have known homologues. Peptides derived from predicted antigenic sequences near the amino terminus of six of these proteins, and another seven peptides derived from the two known surface proteins, GRAB and MtsA, were conjugated to keyhole lymphocyanin (KLH), and investigated for their capacity to induce opsonic antibody responses in outbred Quackenbush mice. All peptide-KLH antisera demonstrated opsonic capacity against both 88/30 and M1 GAS. However, KLH sera alone was also able to induce opsonic antibodies, suggesting that anti-KLH antibodies contributed to the opsonisation seen in the peptide-KLH antisera. KLH is therefore a promising carrier molecule for potential GAS peptide vaccines.
Similar articles
-
Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.BMC Microbiol. 2006 Aug 9;6:71. doi: 10.1186/1471-2180-6-71. BMC Microbiol. 2006. PMID: 16895610 Free PMC article.
-
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.J Infect Dis. 2006 Jun 15;193(12):1666-76. doi: 10.1086/504266. Epub 2006 May 10. J Infect Dis. 2006. PMID: 16703510
-
Prospecting for new group A streptococcal vaccine candidates.Indian J Med Res. 2004 May;119 Suppl:121-5. Indian J Med Res. 2004. PMID: 15232176
-
Group A streptococcal vaccines: facts versus fantasy.Curr Opin Infect Dis. 2009 Dec;22(6):544-52. doi: 10.1097/QCO.0b013e328332bbfe. Curr Opin Infect Dis. 2009. PMID: 19797947 Review.
-
Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?Expert Rev Vaccines. 2009 Dec;8(12):1705-20. doi: 10.1586/erv.09.133. Expert Rev Vaccines. 2009. PMID: 19905872 Review.
Cited by
-
Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs.Infect Immun. 2006 Jan;74(1):305-12. doi: 10.1128/IAI.74.1.305-312.2006. Infect Immun. 2006. PMID: 16368985 Free PMC article.
-
Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.Immunol Res. 2006;35(3):233-48. doi: 10.1385/IR:35:3:233. Immunol Res. 2006. PMID: 17172649 Review.
-
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.Sci Rep. 2016 Feb 25;6:22030. doi: 10.1038/srep22030. Sci Rep. 2016. PMID: 26911649 Free PMC article.
-
Bioinformatics and multiepitope DNA immunization to design rational snake antivenom.PLoS Med. 2006 Jun;3(6):e184. doi: 10.1371/journal.pmed.0030184. PLoS Med. 2006. PMID: 16737347 Free PMC article.
-
Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.Vaccines (Basel). 2019 Jul 1;7(3):58. doi: 10.3390/vaccines7030058. Vaccines (Basel). 2019. PMID: 31266253 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical